In a bold move shaking South Korea’s biotech landscape, Samsung Biologics employees extended their groundbreaking strike into day five on Tuesday. Union members, representing a significant portion of the workforce, are united in pushing for better wages and bonuses amid stalled negotiations.
Launched last Friday, the action saw 2,800 of the union’s 4,000 members participate—the first such event since the company’s 2011 inception. This labor unrest highlights deepening divides between workers and management over compensation structures.
Key demands include a 14% boost to base and performance-linked salaries, a 30 million won lump-sum incentive per employee (roughly $20,390), and profit-sharing bonuses at 20% of yearly operating earnings. Samsung’s offer? A combined 6.2% raise, which the union deems insufficient.
Monday’s talks yielded no breakthroughs, though additional sessions are planned before the weekend. Following the strike’s conclusion, workers intend to implement ‘work-to-rule’ measures from Wednesday, potentially slowing productivity to pressure the company.
The strike’s bite is evident in the numbers. Last month’s three-day partial stoppage inflicted 150 billion won ($101.5 million) in damages. Current projections warn of up to 640 billion won in losses—equivalent to nearly half the first-quarter revenue.
A company source described their engagement with labor ministry mediators as a sincere push for talks, calling on the union to abandon ‘irrational’ asks and resume constructive dialogue. Last week’s mediation hit a snag when the union sought to replace its entire bargaining team.
As global demand for biologics surges, this dispute threatens Samsung Biologics’ supply chain role. The coming days’ negotiations could either avert deeper crisis or escalate into prolonged industrial action, setting precedents for Korea’s tech-biotech nexus.
